Scholarlink

Background <p>Cardiovascular disease is the leading cause of death among patients undergoing hemodialysis, while effective preventive strategies remain limited. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have demonstrated cardiovascular benefits in the general population. We evaluated the effects of n-3 PUFA supplementation in adults receiving hemodialysis.</p> Methods <p>PubMed, Embase, and CENTRAL were searched through November 2025 for randomized controlled trials (RCTs) comparing n-3 PUFAs versus placebo in adult hemodialysis patients. Data were pooled using a random-effects model and reported as risk ratios (RR) or mean differences (MD) with 95% confidence intervals (CI). Subgroup analyses were performed based on Diabetes, Hypertension, Age and Follow-up.</p> Results <p>n-3 PUFA supplementation did not significantly reduce all-cause mortality (RR = 0.93; 95% CI 0.80–1.08; <i>p</i> = 0.33). In contrast, cardiovascular mortality was significantly reduced (RR = 0.55; 95% CI 0.42–0.71; <i>p</i> &lt; 0.001) along with fewer vascular access related events (RR = 0.83; 95% CI 0.73–0.95; <i>p</i> = 0.005). significant effects were observed for fatal or non-fatal MI (RR = 0.50; 95% CI 0.36–0.68; <i>p</i> &lt; 0.001).</p> Conclusions <p>n-3 PUFA supplementation significantly reduces cardiovascular mortality, myocardial infarction, and vascular access events in hemodialysis patients without affecting all-cause mortality. While these findings support n-3 PUFAs as adjunctive cardioprotective therapy in this population, the concentration of evidence in a single large trial warrants cautious interpretation, and confirmation from further large RCTs remains necessary.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of OMEGA-3 fatty acid in patients undergoing hemodialysis: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月19日

查看全文
  • Hafiz Bilal Ahmed Jilani,
  • Burhan Mazhar Baig,
  • Anas Rasool,
  • Muhammad Ibrahim,
  • Ayan Khalid,
  • Muhammad Shaharyar Rizvi,
  • Shaikh Muhammad Daniyal,
  • Amna Amir Jalal,
  • Alishba Arfan,
  • Zaid Abdul Samad,
  • Muhammad Saad,
  • Hammad Rao,
  • Junaid Jalaluddin,
  • Romal Jabarkhil

摘要

Background

Cardiovascular disease is the leading cause of death among patients undergoing hemodialysis, while effective preventive strategies remain limited. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have demonstrated cardiovascular benefits in the general population. We evaluated the effects of n-3 PUFA supplementation in adults receiving hemodialysis.

Methods

PubMed, Embase, and CENTRAL were searched through November 2025 for randomized controlled trials (RCTs) comparing n-3 PUFAs versus placebo in adult hemodialysis patients. Data were pooled using a random-effects model and reported as risk ratios (RR) or mean differences (MD) with 95% confidence intervals (CI). Subgroup analyses were performed based on Diabetes, Hypertension, Age and Follow-up.

Results

n-3 PUFA supplementation did not significantly reduce all-cause mortality (RR = 0.93; 95% CI 0.80–1.08; p = 0.33). In contrast, cardiovascular mortality was significantly reduced (RR = 0.55; 95% CI 0.42–0.71; p < 0.001) along with fewer vascular access related events (RR = 0.83; 95% CI 0.73–0.95; p = 0.005). significant effects were observed for fatal or non-fatal MI (RR = 0.50; 95% CI 0.36–0.68; p < 0.001).

Conclusions

n-3 PUFA supplementation significantly reduces cardiovascular mortality, myocardial infarction, and vascular access events in hemodialysis patients without affecting all-cause mortality. While these findings support n-3 PUFAs as adjunctive cardioprotective therapy in this population, the concentration of evidence in a single large trial warrants cautious interpretation, and confirmation from further large RCTs remains necessary.